why choose us

First received: January 13, 2023

Clinical Trial: CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Pancreatic Ductal Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase I Clinical Trial of CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

Brief Summary: This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable).CA-4948 is in a class of medications called kinase inhibitors.It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4)…

Read more